Title: Immunosuppressive tumor microenvironment of osteosarcoma

Authors: Aaron Michael Taylor[1], Patrick Kwok Shing Ng[1], Jeffrey M Harder[2], Parveen Kumar[1], Alissa M. Dzis[1], Nathaniel L. Jillette[1], Andrew Goodspeed[3], Avery Bodlak[3], Qian Wu[4], Michael S. Isakoff[4,5], Joshy George[1], Jessica D.S. Grassmann[1], Diane Luo[1], William F. Flynn[1], Elise T. Courtois[1], Paul Robson[1], Masanori Hayashi[3,6], Alini Trujillo Paulillo[7], Silvia Regina Caminada de Toledo[7], Fabiola Sara Balarezo[8], Adam D. Lindsay[8], Bang Hoang[9], Ching C. Lau[1,4,5]

1. The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032
2. The Jackson Laboratory, Bar Harbor, ME 04609
3. University of Colorado Anschutz Medical Campus, Aurora, CO 80045
4. University of Connecticut School of Medicine, Farmington, CT 06032
5. Connecticut Children's Medical Center, Hartford, CT 06106
6. Children's Hospital Colorado, Aurora, CO 80045
7. Hospital do GRAACC, São Paulo, Brazil
8. Hartford Hospital, Hartford, CT 06106
9. Montefiore Medical Center, Bronx, NY 10467

Abstract

Background – Osteosarcoma (OS) is the most common malignant bone tumor in children. OS is characterized by a high degree of genomic instability, resulting in copy-number alterations and genomic rearrangements with no disease-defining recurrent mutations. Given the diverse genomic landscape of OS and the difficulty of identifying druggable therapeutic targets, use of immunotherapy techniques appears lucrative. However, clinical trials based on molecular characterization have failed to find new effective therapies, and outcomes have not improved over the last 40 years.

Materials/Methods – We performed single-cell RNA sequencing (scRNA-seq) using the 10x Genomics Chromium platform on six fresh tumor biopsy samples from pediatric OS patients. Raw data was processed using 10x CellRanger to produce transcript read counts for each cell. After filtering low-quality cells and doublet removal, counts were normalized using Seurat, and cells were integrated across samples with Harmony. Data was combined with a previously-published OS scRNA-seq cohort of six samples (GSE162454). Two additional OS samples were profiled using 10x Genomics Visium spatial transcriptomics for validation of discovered subtypes and to add spatial context.

Results – Clustering identified 16 major cell types based on expression of canonical cell markers. Several immunosuppressive cell types were identified via subclustering of major cell types, including neutrophil myeloid-derived suppressor cells (MDSCs), regulatory and exhausted T-cells, and LAMP3+ dendritic cells. Markers for the cell types found in OS were identified for further validation using imaging techniques, including Visium spatial transcriptomics. We performed deconvolution using the scRNA-seq cell identities to examine colocalization of discovered cell types. Overall, the discovered clusters were common between patients, showing consistent cell type proportions. However, we found patient-specific differences in the frequency of some cell types, with one sample showing a higher proportion of T-cells along with increased presence of colocalized IFN-stimulated macrophages, and the other with a greater presence of neutrophils/MDSCs.

Conclusions – Using single-cell transcriptomics, we were able to discover the presence of multiple immunosuppressive cell subtypes of neutrophils, T-cells, and dendritic cells. Additionally, spatial transcriptomics revealed multiple similar clusters between samples, and common colocalization of the discovered cell types within those clusters. However, differences in T-cell presence and interferon induction may be indicative of patient-specific immunogenicity in osteosarcoma tumors.

Introduction:

Osteosarcoma (OS) is the most common primary malignant bone tumor affecting children and young adults. Current treatment with chemotherapy and surgical resection results in a long-term overall survival rate of ~70% for patients with localized disease but only 20-30% for patients with metastatic disease [1]. No significant advances in treatment or overall survival rate have been made in the last four decades.

Genomic profiling studies of OS tumors from predominantly pediatric populations have shown high levels of chromosomal structural variation, including massive rearrangements resulting from chromothripsis and hypermutation in localized regions (kataegis) that contribute to significant tumoral heterogeneity [2]. Because of their potential to generate novel rearrangements in protein-coding sequences, the genomic structural abnormalities observed in OS would be expected to express neoantigens that should serve as potent targets for immunotherapy (IT). Aligning with that, a study of 48 OS patients demonstrated that PD-L1 expression was found in 25% of primary OS samples and correlated with immune cell infiltration and event-free survival [3]. Anti-PD-L1 and anti-CTLA4 treatment also controlled OS tumor growth in a mouse model [4]. However, the clinical trials using anti-PD-L1 and anti-CTLA4 have not shown any efficacy in OS treatment [5, 6].

The tumor microenvironment (TME) of multiple cancers has been shown to play a critical role in tumor progression and treatment response [7]. Previous studies of the OS TME have revealed the presence of multiple immune cell types, e.g., dendritic cells (DCs), macrophages, neutrophils, and lymphoid cells, with a wide range of cell abundance across patient samples [8-10]. However, the role of these tumor-infiltrating immune cells in OS is not fully understood. With the recent advancements in single-cell technologies, several groups have applied single-cell RNA sequencing (scRNA-seq) analysis on limited populations of OS patient tumors, including biopsy, post-treatment surgical resection, and lung metastasis samples [11, 12]. Apart from the heterogeneous OS tumor cells, those studies also identified several molecular subtypes of immune cells, including *TIGIT+* exhausted T cells, *FOX3P+* regulatory T cells, and *LAMP3+* mature regulatory DCs [11-13]. Taken together with the failure of the IT clinical trials, the complex TME within OS may serve an immunosuppressive function. Thus, a better understanding of the OS TME is urgently needed to improve the IT efficacy for OS patients.

To advance our understanding of the OS TME naïve to chemotherapy-induced biological changes, we performed scRNA-seq analysis on six pre-treatment primary tumor biopsy samples of OS. We successfully combined our data with the previously-published six pre-treatment OS sample data [11] to increase our ability to detect rare cell types or subtypes. We described a number of immune cells that potentially contribute to the tumor progression and immunosuppressive TME using subclustering, differential gene expression, and pathway analysis. In addition, we evaluated the spatial distribution of those cell types of interest by spatial transcriptomics analysis on additional pre-treatment biopsy samples of OS.

Material and Methods:

Sample Collection and Tissue Dissociation

Tumor tissue specimens of six OS patients were collected at Connecticut Children's Medical Center (CCMC) or Children's Hospital Colorado (CHCO). All specimen collection and experiments were reviewed and approved by the Institutional Review Board of CCMC or CHCO, respectively. Written informed consent was obtained prior to acquisition of tissue from patients. Diagnosis was confirmed by pathologist assessment. The specimens were stored in MACS tissue storage solution (Miltenyi Biotec, Bergisch Gladbach, Germany). The three CCMC samples were transferred to The Jackson Laboratory for Genomic Medicine for the tissue dissociation process.

For CCMC samples, the tissue specimens were minced and enzymatically dissociated in DMEM medium supplemented with Collagenase II (250U/ml, Gibco #17101-015, Waltham, Massachusetts, USA) and DNase (1µg/ml, Stemcell #07900, Cambridge, Massachusetts, USA) for up to 3 cycles of 37 °C 15 minutes dissociation with agitation. After each cycle, undigested tissue pieces were settled down by gravity and supernatant was transferred to cold Buffer I solution (10% FBS/DMEM medium supplemented by EDTA (2mM) and 2% BSA (Lampire #7500854, Pipersville, Pennsylvania, USA). Fresh dissociation solution was applied to the undigested tissue for next digestion cycle. Cells collected from each cycle were merged, spun down and resuspended with ACK lysis buffer (Gibco #A1049201) to remove red blood cells. After 3 minutes on ice, lysis reaction was quenched by adding Buffer I solution. After centrifugation, cells were resuspended in Buffer I solution and strained through a 70-µm cell strainer. Cells were stained with propidium iodide (PI) and Calcein Violet (Thermo Fisehr Scientific). PI-negative and Calcien Violet-positive viable cells were sorted out using FACSAria Fusion system (BD Biosciences, Franklin Lakes, New Jersey, USA).

For CHCO samples, tissue specimens were viably cryopreserved in 90% FBS 10%DMSO immediately after collection. Tissue specimens were thawed at 37 °C, then enzymatically dissociated in a 0.1% DNase and Liberase 400µg/mL (Roche/Sigma-Aldrich, St. Louis, Missouri, USA) cocktail. Cells were then selected for viability using the FACSAria I cell sorter (BD Biosciences) in the Allergy and Clinical Immunology Flow Cytometry Facility at the Division of Allergy and Clinical Immunology, University of Colorado School of Medicine.

Single-Cell Capture, Library Preparation and RNA-seq
Cells were washed and resuspended in PBS containing 0.04% BSA. Cells were counted on Countess II automated cell counter (Thermo Fisher, Waltham, Massachusetts, USA), and up to 12,000 cells were loaded per lane on 10x Chromium microfluidic chips (10x Genomics, Pleasanton, California, USA). Single-cell capture, barcoding, and library preparation were performed using the 10x Chromium X version 3 chemistry [14], and according to the manufacturer's protocol. cDNA and libraries were checked for quality on Agilent 4200 Tapestation and quantified by KAPA qPCR before sequencing using a Novaseq 6000 (Illumina, San Diego, California, USA) v1.5 cycle flow cell lane at 100,000 reads per cell, with a 28-10-10-90 asymmetric read configuration.

Single-Cell Data Processing and Quality Control
10X Genomics *Cell Ranger* (3.0.2) was used for read alignment (version 3.0.0, GRCh37) and count matrix generation (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger). Reads from each sample were initially filtered using multiple criteria: during FASTQ generation, reads with more than one mismatch in the 8bp i7 index are excluded. Alignment using *STAR* [15] as performed, and only reads aligned to annotated transcripts with MAPQ scores greater than 255 are retained. Reads containing bases with Q30 scores below 3 are also excluded.

Following alignment, cell barcodes were filtered against a whitelist of barcodes provided by 10X Genomics (<2 mismatches). Barcodes associated with cells are distinguished from those associated with ambient mRNA using an adaptively computed UMI threshold via *Cell Ranger*, and a digital counts matrix is generated for each sample. Single-cell RNA expression data from an additional 6 samples described in Liu et al. [11] was downloaded from the Gene Expression Omnibus (GSE162454).

For all samples, additional preprocessing was performed using *Seurat* (version 4.0.5) [16] in R (version 4.1.1) [17]. For each cell, the percentage of reads mapping to mitochondrial and ribosomal genes was calculated, and cells were filtered out according to the following criterion: >20% mtRNA, >50% rRNA, or <500 features expressed. Doublet detection and removal was performed using the *R*-package *DoubletFinder* (default parameters) [18]. Read counts for each cell were log-normalized

(scale factor=1e6), and the top 2000 variable features (selection method="vst") in the data set were calculated. Data was scaled and corrected for cell cycle score and percentage of mitochondrial RNA ("CellCycleScoring" and "ScaleData" functions, vars.to.regress = c("percent.mt", "S.Score", "G2M.Score")) prior to principal component analysis (PCA). *Harmony* (version 0.1.0) [19] was used to correct the top 50 principal components for patient sex and sample source site prior to downstream clustering analyses.

Clustering and Cell Type Determination
Primary cell clustering was performed using *Seurat*'s "FindClusters" function (*Harmony*-correct PCs = 40, res = 0.25). The "FindAllMarkers" function (only.pos=TRUE, min.pct = 0.25, logfc.threshold = 0.25, test.use = "bimod" [20]) was utilized to detect markers for each cluster, with major cell types annotated using a known set of genes, specifically Macrophage/DC (*MSR1, C1QC, FOLR2*), Osteosarcoma (*SATB2, IBSL, ALPL*), NK/T-cell (*CD3D, TRBC1, NKG7*), Osteoclast (*ACP5, CTSK, MMP9*), Monocyte/Neutrophil (*S100A8, S100A9, FCN1*), Fibroblast (*TAGLN, ACTA2, FAP*), Endothelial (*CLEC14A, PLVAP, VWF*), B-cell (*MS4A1, CD79A, BANK1*), Plasma cell (*IGHG1, IGLC2, IGHG4*), and Mast cell (*TPSB2, TPSAB1, CPA3*), as well proliferation markers (*MKI67, TOP2A, TYMS*).

Subsequently, major cell types were subclustered in order to detect cell subtypes. We used the "subset" function for major cell clusters, reperformed normalization ("CellCycleScoring" and "ScaleData" functions, vars.to.regress = c("percent.mt", "CC.Difference")), and *Harmony* correction of PCs. Subclustered cell types include macrophage/DCs (PCs=30, res=0.2), osteosarcoma/fibroblasts (PCs=40, res=0.15), osteoclasts (PCs=30, res=0.1), neutrophils (PCs=30, res=0.1), and proliferative macrophages/DCs (PCs=30, res=0.3). For the NK/T-cell cluster, subtypes were identified using *Azimuth* [16]. Cells within the NK/T-cell cluster were mapped to NK/T-cell L1 annotations within the reference proliferating blood mononuclear cell (PBMC) dataset [21], and cells with a confidence score >0.75 were retained for downstream analysis.

Copy Number Analysis
In order to characterize overall copy number changes between the identified osteosarcoma populations, as well as to detect subclones within each major cluster, *inferCNV* (version 1.10.0) [22] as implemented on a sample-specific basis (cutoff=0.1, HMM=T, denoise=T, analysis_mode="subclusters", hclust_method="ward.D2", cluster_by_groups=TRUE). All normal cell populations were used for comparison.

Cell-cell interactions
iTALK (version 0.1.0) [23] was utilized for the determination of cell-cell interactions. Briefly, positively differentially expressed genes (*Seurat*'s "FindAllMarkers" function, options: BH-adjusted p < 0.05, min.pct = 0.25, logfc.threshold = 0.25, test.use = "bimod"[20]) of previously-annotated selected cell types (osteosarcoma, macrophage, CD4+ T-cell, CD8+ T-cell, exhausted T-cell, regulatory T-cell, myeloid-derived suppressor cell) were queried for known ligand-receptor pairs using the curated *iTALK* database, with interacting pairs were separated by category ("growth factor", "cytokine", "checkpoint", "other") for downstream analysis. For each cell type, ligand-role interactions were determined for each other receptor-role subtype.

Visium Spatial Gene Expression Analysis
Formalin-fixed, paraffin-embedded (FFPE) samples of two primary OS pre-treatment biopsy tissue samples (Patients A and B) were obtained from CCMC and stored at 4 °C in the dark. Prior to Visium transcriptomics, RNA quality of FFPE samples was determined by DV200 score using Agilent (Santa Clara, California) TapeStation 4200 High Sensitivity DNA ScreenTape. Tissue blocks with DV200 scores above 50% were used for downstream processing. Briefly, FFPE sections were placed on a 10x Visium FFPE Gene Expression slide, deparaffinized, H&E stained, then imaged in brightfield

using a NanoZoomer SQ (Hamamatsu Photonics, Shizuoka, Japan) slide scanner, followed by incubation with human-specific probe sets provided by the manufacturer for subsequent mRNA labeling and library generation per the manufacturer's protocol (10x Genomics, CG000407). Library concentration was quantified using a Tapestation High Sensitivity DNA ScreenTape (Agilent) and fluorometry (Thermofisher Qubit) and verified via KAPA qPCR. Libraries were pooled for sequencing on an Illumina NovaSeq 6000 200-cycle S4 flow cell using a 28-10-10-90 read configuration, targeting 100,000 read pairs per spot covered by tissue.

Illumina base call files for all libraries were converted to FASTQs using bcl2fastq v2.20.0.422 (Illumina). Whole Visium slide images were uploaded to a local OMERO server. For each capture area of the Visium slide, a rectangular region of interest (ROI) containing just the capture area was drawn on the whole slide image via OMERO.web, and OMETIFF images of each ROI were programmatically generated using the OMERO Python API. FASTQ files and associated OMETIFF corresponding to each capture area were aligned to the GRCh38-specific filtered probe set (10x Genomics Human Probeset v1.0.0) using the version 2.1.0 *Space Ranger* count pipeline (10x Genomics).

Seurat (version 4.3.0) [16] was used for normalization, filtering, dimensional reduction, and visualization of the resulting gene expression data. Each section was processed independently. Spots with fewer than 1500 UMIs and 500 genes were removed. Normalization was performed using the "SCTransform" function in *Seurat,* with batch correction performed using *Harmony* (version 0.1.1) [19]. Unsupervised clustering was performed in *Seurat* using Leiden clustering ("FindClusters") [24]. Cell type fractions within spots were estimated using Robust Cell Type Decomposition (RCTD, *spacexr* package version 2.1) [25] and the single cell RNA-seq data as the reference. Sixteen cell types identified above were used, including three major cell classes (Osteosarcoma, Endothelial, and Osteoclast) and 13 immune cell subtypes. The "Immune" fraction shown was the sum of all the individual subtype contributions. Differences in cell type composition between clusters were determined via a one-sided Wilcoxon rank sum test [26] for positive enrichment. Differences in pathway activity were calculated using *PROGENy* (version 1.14) [27].

Results:

Single-cell transcriptomic analysis of treatment-naïve osteosarcoma

The tumor microenvironment (TME) plays a critical role in tumor progression and treatment response [28-30]. Chemotherapy, as the standard treatment regimen for OS, will change the composition of the TME. To identify the TME cellular composition and understand the role of different cell types on tumor progression and treatment response without the influence of treatment, we aimed to investigate the TME of treatment-naïve OS tumors. We carried out scRNA-seq of six treatment-naïve OS tumors (**Supplementary Table S1**) using the 10X Genomics Chromium platform. After quality control and doublet removal, we obtained a dataset of 22,035 cells from six OS tumors (**Supplementary Table S1**). The number of detected UMIs ranged from 694 to 155,389 per cell, with the number of detected genes ranging from 500 to 8,709. To increase our power to identify rare cell types or subtypes, we leveraged the published scRNA-seq dataset from another six treatment-naïve tumors (GSE162454). A total of 40,588 additional cells passed our internal quality control filters and were subsequently integrated with our dataset using the *Harmony* package. A combined dataset with a total 62,623 cells from 12 treatment-naïve OS tumors was generated. New data generated from our scRNA-seq cohort contributes 35.19% of cells to the combined dataset (**Supplementary Table S1, Supplementary Table S2**).

To determine the cellular composition of the tumors, we performed unsupervised clustering via *Seurat*'s graph-based clustering method. Seventeen major clusters were identified (**Figure 1A**). Cell type identification of each cluster was made based on the cluster-specific differential gene expression (**Supplementary Table S3**) and literature-based cell type markers. The expression of each marker

gene was shown in **Figure 1D**. We identified two clusters of macrophages/DCs (*MSR1, C1QC, FOLR2*), six clusters of osteoblastic tumor cells (*SATB2, IBSL, ALPL*), one cluster of natural killer (NK) and T-cells (*CD3D, NKG7 and TRBC1*), osteoclasts (*ACP5, CTSK, MMP9*), monocytes/neutrophils (*S100A8, S100A9, FCN1*), fibroblasts (*TAGLN, ACTA2, FAP*), B-cells (*MS4A1, CD79A, BANK1*), plasma cells (*IGHG1, IGLC2, IGHG4*), mast cells (*TPSB2, TPSAB1, CPA3*) and endothelial cells (*CLEC14A, PLVAP, VWF*). The smallest cluster contained only 36 cells (0.06% of total cells) with no known cell type marker identified, and poor total gene and UMI counts compared to the other clusters. It was assigned as a cluster comprised of low-quality cells and removed prior to downstream analyses. Except for the low-quality cluster and one osteoblastic tumor cell cluster, each cluster consisted of cells from both published and our new datasets (**Figure 1B, Supplementary Figure 1**). The proportion of each cell type and distribution of cells in UMAP is similar between the published and new datasets (**Figure 1B** and **1C**). Since the cells in each significant cluster also expressed well-known, cell-type-specific genes, merging the two datasets was successful.

Macrophages and dendritic cells
The roles of different immune cells in the TME can be diverse and highly dependent on their phenotypic status. To understand the role of different subtypes of immune cells in OS, we looked further into the phenotypic subtypes of various immune cells. First, we investigate the most abundant cell lineage – myeloid cells. Two major myeloid cell clusters were identified in the present dataset – a predominantly macrophage cluster and a macrophage/DC cluster that expressed proliferative markers. While both clusters have strong expression of macrophage markers (*MSR1, C1QC, FOLR2*), the proliferative macrophage/DC cluster also has expression of cell proliferation genes (*MKI67, TOP2A, TYMS*) (**Figure 1D**). Further unsupervised clustering of the macrophage cluster revealed seven sub-clusters with distinct differentially expressed genes (**Supplementary Table S4**). We were able to detect classically activated macrophages (*NR4A3, IL1B, CCL3/4, APOE, TXNIP*), *LYVE+* macrophages, interferon-stimulated macrophages (*CXCL10, ISG15, IFIT1*), angiogenic macrophages (*SPP1, ADAM8, VIM, VCAN*) and one macrophage cluster expressing T-cell maker genes (*IL32, NKG7, TRAC*) (**Figure 2A** and **2B**).

Although the role of various phenotypic macrophages in OS is not fully elucidated yet, their contribution to the anti-inflammatory and immunosuppressive TME in OS has been suggested based on literature. The *LYVE+* macrophage subpopulation has been found in multiple human tissues as tissue-resident macrophages and has been demonstrated to support angiogenesis in different tissues [31-35]. In cancer, they have been shown to cooperate with mesenchymal cells in the TME and support tumor growth in a mammary adenocarcinoma model [36]. Two subtypes of macrophages with angiogenesis signatures (*SPP1+, ADAM8+,* and *VIM+,* or *VCAN+, respectively*) were also detected. *SPP1+* and *VCAN+* angiogenic macrophages have been associated with worse clinical outcomes in multiple types of epithelial cancers [37]. The *SPP1+* macrophage cluster also expressed *HMOX1*, which has been shown to play a role in the immunosuppressive program of tumor-associated macrophages (TAM) [38]. The *VCAN+* angiogenic macrophages have high expression of epidermal growth factor (EGF) family genes, including *EREG* and *AREG*. M2-like TAM-secreted EGF has been shown to promote metastasis in ovarian cancer [39]. Interestingly, this population of macrophages also has higher expression of *OLR1*, a marker of myeloid-derived suppressor cells (MDSC) in other tumors [40]. Macrophages expressing T-cell marker genes have been previously found in inflammatory diseases and head and neck squamous cell carcinoma [41, 42], however, their role in the OS TME is unclear.

Subclustering of the proliferative macrophage/DC cluster revealed seven subpopulations, including three subclusters of dendritic cells and four macrophage subgroups (**Supplementary Table S5**). Classic dendritic cells 1 (cDC1s) and cDC2s were identified based on the expression of *CLEC9A, IRF8* and *IDO1* and *CD1C* and *CLEC10A*, respectively (**Figure 2C** and **2D**). We also detected another distinct type of dendritic cells based on high expression of *LAMP3, CCR7,* and *IDO1*. The cDC2 population was found to be more abundant than cDC1 and *LAMP3+* DCs in the tumors studied. The

presence of *LAMP3+* dendritic cells (*LAMP3+* cDCs) or mature regulatory dendritic cells (mregDCs) has also been reported recently in various cancer types, including osteosarcoma [13, 37]. One possible mechanism of mregDCs in immunosuppression in OS TME has been suggested through interaction with regulatory T-cells (T-regs) via *CD274-PDCD1* and *PVR-TIGIT* signaling [13].

Among proliferative macrophages, similar macrophage subtypes were found as discussed previously, including *CCL3-4+/IL1B+* classically-activated macrophages, *SSP1+/LYVE*1+ angiogenic macrophages, and macrophages expressing T-cell associated genes (*IL32+, NKG7, TRAC+*). A population of *MMP9+/IL7R+* macrophages was found only within the proliferative macrophage cluster.

Immunosuppressive neutrophils/Myeloid-derived suppressor cells (MDSC)
Neutrophils have been known to promote tumor growth, angiogenesis, metastasis and inhibit anti-cancer T-cell activity [43]. To investigate the potential immunosuppressive features of neutrophils in OS, subclustering of the monocyte/neutrophil cluster was carried out, which revealed four different cell types, including two populations of *S100A8/9/12+* neutrophils, and one population of each of *CDKN1C+/FCGR3A+* non-classical monocytes and *FN1+/SPP1+* monocyte-like cells (**Figure 3A** and **3B, Supplemental Table S6**). Of note, among the two neutrophil populations, the larger population of neutrophils expressed higher levels of *S100A8/9/12*, and genes previously identified as markers of myeloid-derived suppressor cells (MDSC), including *VCAN, CLEC4E,* and *CSF3R* (**Figure 3C**) [44]. These findings suggest the presence of immunosuppressive neutrophils or MDSC in OS TME and could be one of the major contributors to immunosuppression in OS. In addition, monocyte-like cells are a possible precursor of TAM and can contribute to the accumulation of MDSCs in cancer [45].

Regulatory and Exhausted T-cells
T-cells are essential for the immune anti-tumor response and for the successful administration of immunotherapy [46]. Negative regulation of T-cells, leading to hypofunctional or exhausted T-cells, is a hallmark of many cancers, and understanding the mechanisms that lead to this exhaustion can provide potential targets for immunotherapy development [47, 48]. In order to better understand the T-cell and NK cell subtypes present within the TME of OS, we mapped cells of the NK/T cell cluster (C02) to the peripheral blood mononuclear cell (PBMC) reference dataset [21] using *Azimuth* [16]. We separated populations of NK cells (*NKG7, KLRD1, TYROBP, GNLY, FCER1G, PRF1, CD247, KLRF1, CST7* and *GZMB*), helper *CD4+* T-cells (*IL7R, MAL, LTB, CD4, LDHB, TPT1, TRAC, TMSB10, CD3D* and *CD3G*) and cytotoxic *CD8+* T-cells (*CD8B, CD8A, CD3D, TMSB10, HCST, CD3G, LINC02446, CTSW, CD3E* and *TRAC*) (**Figure 4A** and **4B, Supplementary Table S7**).

We subdivided these categories further using *Azimuth* to detect the major subtypes of NK-cell and T-cell populations (**Figure 4A**). Notably, amongst the *CD4+* T-cells was a robust population of regulatory T-cells (*RTKN2, FOXP3, AC133644.2, CD4, IL2RA, TIGIT, CTLA4, FCRL3, LAIR2* and *IKZF2*) (**Figure 4B** and **4C**). This population represented over 10% (227/2126) of the detected *CD4+* T-cells. Since the PBMC reference does not include exhausted T-cells, to detect this subpopulation, we performed subclustering of the *CD8+* effector memory T-cells (CD8TEM), and looked at the expression of traditional exhaustion markers, specifically *PDCD1, LAG3,* and *TOX* (**Figure 4D** and **4E**). We found that the largest subpopulation of CD8TEM cells had higher expression of all three marker genes, indicating the robust presence of the exhausted T-cell population. Given that CD8TEM also represents the majority of *CD8+* T-cells within the OS samples, T-cell exhaustion within osteosarcoma appears to be prevalent (1249/2610, 48%). Taken together, the significant population of regulatory and exhausted T-cells could be one of the major contributors to the immunosuppressive TME in OS.

Osteosarcoma
Leveraging the large-scale copy number alterations that serve as the signature of osteosarcoma, we utilized *inferCNV* [22] to detect relevant subclones of OS cells with distinct copy number alterations.

We observed several subpopulations with normal arm-level copy number profiles, indicating that normal fibroblast or mesenchymal cells likely existed within our osteosarcoma clusters. In order to remove these, we combined all six OS cell clusters potentially containing normal cells derived from the primary clustering analysis shown in **Figure 1**, and then subclustered the OS cells as a whole (**Supplementary Table S8**) prior to sample-specific *inferCNV* analysis. Subclustering results in 8 subclusters, including two subclusters of normal cells (subclusters 6 and 8) (**Supplementary Figure 2**). After removal of normal cell population, *inferCNV* analysis was carried out on individual patient basis. Between 3 and 8 subclones were observed in patients, with one sample having too few detected osteosarcoma cells to perform *inferCNV*. Several arm level copy number alterations were found recurrently in subclones of OS cells across samples, including CNVs previously reported in osteosarcoma. These CNVs include amplifications of chromosome arms 1p [49], 1q [49-53], 7p [54], 8q [49, 52, 55-60], and 20p [61-63], as well as deletions of 6q [64, 65].

Cell-cell interactions
Next, we sought to investigate how various cell types identified in scRNA-seq analysis interact within the TME to determine their possible role in immunosuppression in OS TME. We utilized *iTALK* [23] to examine ligand-receptor interactions using a curated database of known interacting pairs. We calculated differentially-expressed genes (BH-adj. p-value < 0.05) for selected cell types of interest, and queried *iTALK*'s database for interactions based on this list (**Figure 5A**, **Supplementary Table S3**). We looked specifically at signaling interactions originating from OS, exhausted T-cells, T-regs, and MDSCs in order to determine how this signaling may contribute to immunosuppression within the tumor (**Figure 5B, 5C** and **5D**).

We found robust interaction between osteosarcoma with macrophages, MDSCs, and exhausted T-cells (**Figure 5B), including** multiple previously-identified interactions known to be involved in immunosuppression. For example, *CSF1* (also known as macrophage colony-stimulating factor) was highly expressed in osteosarcoma, and its receptor *CSF1R* was highly expressed in macrophages (**Figure 5E, Supplementary Table S9**). This interaction was shown to contribute to pathological immune activation and MDSC activation/recruitment [66, 67], and has been previously tested as a target for cancer therapy [68]. Regulatory T-cell signaling to exhausted T-cells was also observed. We identified *SELPLG* (PSGL-1) overexpression in regulatory T-cells, which interacts as a ligand with *ITGB2*, which was highly expressed in exhausted T-cells. PSGL-1 expression is an established immune checkpoint regulator whose ligation on exhausted T-cells is associated with upregulated PD-1 and cell death [69].

Since the immunosuppressive role of MDSC has been reported in cancers and serves as an attractive target to improve immunotherapies, we took a deeper look into the MDSC signaling to T-regs and exhausted T-cells. The *iTalk* results suggested four major interactions, LGALS9-HAVCR2, ICAM1/3-ITG receptors (ITGB2, IL2RG and ITGAL), CD86-CTLA4 and TGFB signaling-CXCR4 (**Figure 5E, Supplementary Table S9**). Firstly, high expression of the *LGALS9* (GAL9) on MDSCs and its receptor *HAVCR2* (TIM3) on exhausted T-cells. This interaction is known to suppress anti-tumor immunity [70], and the upregulation of GAL9 in tumors is associated with the expansion of MDSCs [71]. Furthermore, overexpression of GAL9 in MDSCs has been shown to contribute to the exhaustion and apoptosis of CD8+ T-cells through its interaction with TIM3 in myelodysplastic syndrome patients [72]. Secondly, we saw high *ICAM1/3* ligand expression in MDSCs, which binds with several highly-expressed ITG receptors (*ITGB2, IL2RG, ITGAL*) in exhausted T-cells. This interaction was shown to be important for the immunosuppressive function of MDSCs on T-cells [73], independent of other mechanisms such as the production of reactive oxygen species (ROS), and was targetable using blocking antibodies against ICAM-1 [73]. Thirdly, MDSCs had high expression of *CD86*, which could serve as a ligand for *CTLA4* in regulatory T-cells. Antigen-presenting cells expressing CD86 can support the homeostasis of regulatory T-cells through interaction with their cell-type-specific high expression of *CTLA4* [74]. Fourthly, we found *TGFB* signaling originating from

MDSCs and interacting with *CXCR4* on all tested T-cell subtypes. *TGFB* expression in MDSCs has been shown to be immunosuppressive in murine cancer models [75-77].

Spatial transcriptomics

Like other solid tumors, osteosarcoma has complex tissue structure and heterogenous cellular organization. In order to understand the potential immunosuppression from the spatial perspective in the OS TME, we sought to study the cellular organization and architecture of the tissue using spatial transcriptomics analyses with the 10X Genomics Visium platform on two pre-treatment primary tumor biopsy tissue samples. After quality control filtering, normalization, and data integration using *Seurat* [16] and *Harmony* [19], we used Robust Cell Type Decomposition (RCTD) [25] to infer spot-level cell composition and compare the overall cell type frequencies in the two samples. Similar to the scRNA-seq data, these samples primarily consisted of OS cells and immune cells, with populations of endothelial cells and osteoclasts (**Figure 6A**). Among immune cells, we observed sample-specific abundance and many subtypes were uncommon between two samples (**Figure 6B**). For instance, activated macrophages, angiogenic macrophages, and neutrophils/monocytes were more prevalent in Patient A, whereas CD8+ T-cells, CD4+ T-cells, and IFN-stimulated macrophages were observed more in Patient B.

To better understand the cellular distribution of various cell types, eight clusters with unique gene expression patterns were identified by unsupervised clustering of spots (**Figure 6C and 6D**). Four clusters (0-3) defined the largest area of the tumor samples and were common to both samples, whereas other five clusters showed tumor-specific localizations (**Figure 6C and D**). Cell composition contributed to these regional identities based on the enrichment of estimated cell type fractions with each cluster (**Figure 6E**). Both tumors had comparable regions enriched in MDSCs (cluster 0), OS cells (with fewer immune cells, cluster 1), LYVE+ macrophages (cluster 2), or endothelial cells (cluster 3). Patient A had a region marked by neutrophils/monocytes and angiogenic macrophages (cluster 5) and another enriched in activated macrophages and B cells (cluster 7), and Patient B had a region enriched in CD8+ T-cells, CD4+ T-cells, and IFN-stimulated macrophages (cluster 4). Thus, the differences in immune cell composition between samples noted above were largely attributable to localized phenomena.

To understand the biological significance and phenotypes of different regions within the samples, we ran signaling pathway activity analysis – *PROGENy*. Different clusters showed distinguished gene expression patterns associated with cancer-relevant signaling pathways (**Figure 6F**). Common to both tumors, relatively large areas showed gene expression patterns associated with EGFR (cluster 0) and TGFB (cluster 3) signaling pathway activity. Both pathways have been associated with immunosuppression in cancer and response to immunotherapy [78, 79]. Consistent with this, these areas contained immunosuppressive cells like MDSCs (cluster 0) and generally lacked enrichment of anti-tumor cells, like CD8+ T cells. In one sample, we observed a hypoxia-associated gene expression pattern (cluster 5), which also had its own distinct enrichment of immune cell types, including angiogenic macrophages and neutrophils/monocytes clustered with osteoclasts. Finally, the region with the clearest enrichment of CD8+ T cells (cluster 4) lacked enrichment of the EGFR, TGFB, and hypoxia-associated gene expression signatures. Overall, these data, for the first time, showed the spatial distribution of different cell types and cell states, particularly in macrophages, in OS TME. It also suggests that the TME of OS is largely immunosuppressive and its architecture consists of potentially distinct immunosuppressive milieus.

Discussion:

The suboptimal result of recent immunotherapy clinical trials suggested that OS has a complex immune TME. To improve the efficacy of treatment, particularly of immunotherapy, better understanding of OS immune landscape is urgently needed. To address this, we performed scRNA-seq analysis of six treatment naïve OS samples and combined with the published scRNA-seq data of

other six treatment naïve OS samples to generate the largest scRNA-seq data so far. We aimed to better understand the potential immunosuppressive TME in OS by focusing on immune cells identified in OS TME. With the combined dataset, we identified similar immune cell types reported in previous OS scRNA-seq studies [11, 12], including immunosuppressive related cell types, e.g., CD4[+] regulatory T cells and CD8[+] exhausted T cells. Regulatory and exhausted T-cells have well-established roles in the microenvironment of multiple tumors, including osteosarcoma [11-13]. T-cell exhaustion is a hallmark of immune evasion in many cancers, and overcoming this phenomenon in solid tumors is essential for the efficacy of emerging treatments such as CAR-T therapy [80, 81].

Notably, although previous studies showed the presence of neutrophils in OS, we identified two subtypes of neutrophils including a major subtype expressing previous identified myeloid-derived suppressor cell (MDSC) markers. MDSCs contribute to the pathological immune response in cancer and may be potent targets for immunotherapy development [82]. In addition, Zhou et al. [12] noted an increased presence of neutrophils in primary tumors as compared to recurrent tumors using a chemotherapy-treated cohort. Our treatment-naïve cohort of primary tumors also showed a robust population of neutrophils, and given that the majority were immunosuppressive, this likely represents an important axis of immune evasion particularly for primary osteosarcoma and worthy of further investigation.

We also found a population of LAMP3+ cDCs within our internal cohort, which had been previously detected in osteosarcoma and interact with regulatory T cells to perform their immunosuppressive functions [13, 37]. Liu et al. [13] highlighted the interaction between LAMP3+ mregDCs and regulatory T-cells through the interaction of CD274 and PVR with PDCD1 and TIGIT, respectively. This interaction was specific to tumors, indicating the importance of mregDCs in mitigating antitumor immunity in osteosarcoma. Our findings show that the presence of mregDCs is common in osteosarcoma, and emphasizes the importance of further study of this immunosuppressive cell type.

The presence of immunosuppressive and angiogenic TAMs in osteosarcoma was also found in our dataset. Expanding on the previous analyses of macrophages in osterosarcoma [11, 12], we attempted to examine M1-M2 macrophage polarity amongst our macrophage subclusters using the markers from those studies, and we also saw no evidence of MKI67+ tissue resident macrophages (**Supplementary Figure S4**). However, we did not observe strong evidence of M1 and M2 macrophage polarity in our dataset which aligns with the argument that macrophages have more complex phenotype than M1 and M2 polarity. In our analysis, distinct phenotypic macrophages were found, including classic activated macrophages, angiogenic macrophages, and interferon-stimulated macrophages, based on distinct markers for each subcluster. Additionally, subclustering revealed a distinct population of LYVE+ angiogenic macrophages previously found in several cancer subtypes [31-35]. Although the exact role of each macrophage subtype in OS TME is largely unknown, as the most abundant immune cell types with distinct phenotypes, macrophages are attractive targets for future immunotherapy development.

Previous analysis by Liu et al. [11] found four major subpopulations of osteoclast. Specifically, they noted populations of mature osteoclasts (*CTSK*, *ACP5*, *MMP9*), proliferative progenitor osteoclasts (*CD74*, *CD14*, *HLA-DRA*, *MKI67*, *CTSK*^*lower*^, *ACP5*^*lower*^, *MMP9*^*lower*^) and non/hypofunctional osteoclasts with low expression of such markers. Although not a focus of this study, subclustering of osteoclasts revealed a population of progenitor osteoclasts positive for progenitor markers *CD74*, *CD14*, *HLA-DRA* and *MKI67*, as well as the proliferation marker *TOP2A*, matching the previous results (**Supplementary Figure S3**). However, the other four populations of osteoclasts seemed to closely match the more mature osteoclasts subtypes with few distinctive differentially expressed genes, and there weren't strong indications of separate hypofunctional or nonfunctional osteoclast subtypes. Further analysis of the four mature osteoclast subtypes may reveal unique phenotypes.

Finally, we examine spatial transcriptomics on two pre-treatment biopsy samples to verify the presence of these immunosuppressive cell types and to examine how they colocalize within osteosarcoma and therefore indicating potential interactions. We found distinctions between those samples in their immune cell population prevalence, which broadly indicate differences in interferon stimulation and macrophage subtypes. Osteosarcoma cells, MDSCs, and *LYVE+* macrophages were comparable between the two samples, indicating some commonality between the tumors. However, given the importance of the different immune cell population frequencies between these two tumors, which also showed differences in pathway expression related to growth factor expression, more spatial transcriptomics data is needed to further explore cellular heterogeneity in osteosarcoma and how this may affect treatment and survival outcomes. Taken together, our findings suggest a broad network of pathological immunosuppression within osteosarcoma. Although we should be careful to avoid inferring too much from our observations without further orthogonal validation and functional studies to confirm our findings, it would be prudent to explore the incorporation of treatment strategies aimed at addressing the observed immunosuppressive signaling within osteosarcoma.

Conflict of Interest Statement
The authors declare no conflict of interest.

Data Availability Statement
Internal single-cell RNA expression and Visium spatial transcriptomics data will be made available upon reasonable request. The data will be uploaded to the Gene Expression Omnibus upon final publication. Single-cell RNA expression data from the external cohort of 6 samples was downloaded from the Gene Expression Omnibus (GSE162454).

Figures

Figure 1: Primary clustering identifies major cell types in pre-treatment osteosarcoma tumors. **(A)** UMAP visualization of *Harmony*-corrected principal components, with cell type clusters separated by color. **(B)** Cell type proportions of each sample cohort. Macrophages and osteosarcoma were the most abundant cell types in both cohorts. **(C)** UMAP visualization of *Harmony*-corrected principal components in each cohort. **(D)** Expression of selected cell-type-specific markers in major cell clusters. Markers were chosen from the differentially expressed genes in **Supplemental Table 2** based on fold-change, cell cluster specificity, and their prior published use as cell type markers.

Figure 2: Subclustering of macrophage/DC clusters **(A)** UMAP visualization of *Harmony*-corrected principal components of the macrophage cluster. Cell subtypes separated by color. **(B)** Expression of selected cell-subtype-specific markers amongst macrophage subclusters. Several subtypes of activated, interferon (IFN)-stimulated, and angiogenic macrophages were identified. **(C)** UMAP visualization of *Harmony*-corrected principal components of the proliferative macrophage/DC cluster. Cell subtypes separated by color. **(D)** Expression of selected cell-subtype-specific markers amongst macrophage/DC subclusters. *LYVE+* macrophages were detected, along with populations of cDC1 and cDC2, in addition to a putative *LAMP3*+ mregDC population.

Figure 3: Identification of MDSCs amongst neutrophil/monocyte population **(A)** UMAP visualization of *Harmony*-corrected principal components of major neutrophil/monocyte cluster. Cell subtypes separated by color. **(B)** Dotplot expression of selected markers amongst neutrophil and monocyte subclusters ("N-CM" = non-classical monocyte). **(C)** Visualization of MDSC feature expression. *Seurat*'s "AddModuleScore" function was used to create an S100A gene expression score in the leftmost plot. Expression of other MDSC signature genes (*VCAN*, *CLEC4E* and *CSF3R*) is also shown.

Figure 4: Identification of NK/T-cell subtypes using *Azimuth* **(A)** Identified NK/T-cells and their subtypes. Cells identified with >0.75 confidence score were mapped to *Azimuth*'s "L1" identities ('Major Cell Cluster') from the reference "PBMC" dataset. Further annotation using the "L2" cell identities ('Specific Cell Type') is also shown, along with a subset of the signature genes that define those cell subtypes. **(B)** UMAP visualization of *Harmony*-corrected principal components of identified NK/T-cell populations, colored by L1 identities. **(C)** NK cell, CD4+ T-cell, and CD8+ T-cell scores were created using *Seurat*'s "AddModuleScore" function from the *Azimuth*-defined cell type markers. **(D)** UMAP visualization of *Harmony*-corrected principal components of identified CD8 T-effector-memory (CD8TEM) cell subpopulations. **(E)** Dotplot expression of exhaustion markers amongst CD8TEM subpopulations. Exhaustion markers were overexpressed in the largest subcluster of CD8TEMs.

Figure 5: iTALK ligand-receptor interactions by subtype. **(A)** Overall ligand-receptor interactions across tested cell types. Arrow indicates ligand-reception directionality, line thickness corresponds to the number of interactions. Only interactions where significant differential expression of the ligand or receptor in the corresponding cell type are shown **(B)** Network plot showing significant osteosarcoma signaling (ligand only) interactions with other cell types. **(C)** Network plot showing significant regulatory T-cell signaling (ligand only) interactions with other cell types. **(D)** Network plot showing significant neutrophil/MDSC signaling (ligand only) interactions with other cell types. **(E)** Cartoon displaying selected significant ligand/receptor interactions with prior literature information.

Figure 6: Spatial transcriptomics analysis of osteosarcoma **(A)** Estimated fractions of major classes of cell types per spot as determined by deconvolution using RCTD and the single cell reference dataset. The Immune class was aggregated from values inferred for 12 subtypes of immune cells. Osteosarcoma, Endothelial, and Osteoclast were calculated directly. **(B)** Estimated fractions of 13 immune cell subtypes per spot inferred by deconvolution showed variability between patients. **(C)**

H&E images overlayed with spot cluster membership determined by unsupervised clustering of gene expression defining regional patterning. **(D)** Cluster membership information depicted as a UMAP plot (left) and as a percent of total spots for each patient (right). **(E)** Heatmap with z-scores based on the median cell type fraction per cluster. **(F)** Heatmap with z-scores based on the median PROGENy scores per cluster. These scores of relative pathway activity based on weighted gene expression levels were calculated per spot. Asterisks indicate the adjusted significance level for enrichment determined by one-sided Wilcoxon rank sum test. Spots in a single cluster were compared to all other spots. *, P<0.05; **, P<0.01; ***, P<0.001.

Supplementary Figures
Supplementary Figure S1: Major cell type proportions of each sample.
Supplementary Figure S2: *inferCNV* plots for each sample.
Supplementary Figure S3: Osteoclast subtype markers used by Liu et al. [11] plotted across our identified osteoclast subclusters.
Supplementary Figure S4: M1/M2/tissue-resident macrophage (TRM) subtype markers used by Liu et al. [11] and Zhou et al. [12] and plotted across our identified osteoclast subclusters.

Supplementary Tables
Supplementary Table S1: Patient and sample characteristics.
Supplementary Table S2: Frequency table of the contribution to the primary clusters by (**a**) sample, (**b**) patient sex, and (**c**) cohort. (**d**) Major cluster membership of each cell.
Supplementary Table S3: Full gene list showing markers for each primary cluster.
Supplementary Table S4: (**a**) Frequency table of the contribution to the macrophage subclusters by sample. (**b**) Macrophage subcluster membership of each cell. (**c**) Cell markers of each macrophage subcluster.
Supplementary Table S5: (**a**) Frequency table of the contribution to the proliferative macrophage/DC subclusters by sample. (**b**) Proliferative macrophage/DC subcluster membership of each cell. (**c**) Cell markers of each proliferative macrophage/DC subcluster.
Supplementary Table S6: (**a**) Frequency table of the contribution to the monocyte/neutrophil subclusters by sample. (**b**) Monocyte/neutrophil subcluster membership of each cell. (**c**) Cell markers of each monocyte/neutrophil subcluster.
Supplementary Table S7: (**a**) *Azimuth* output showing the predicted cell types/subtypes of the NK/T cluster cells after mapping to the PBMC data. Cells that mapped to NK or T-cell clusters by Azimuth with a confidence score > 0.75 were retained for downstream analysis (**b**) Frequency table of the contribution to the NK/T-cell L2 subtypes by sample.
Supplementary Table S8: (**a**) Frequency table of the contribution to the osteosarcoma/normal fibroblast subclusters by sample. (**b**) Osteosarcoma/normal fibroblast subcluster membership of each cell. (**c**) Cell markers of each osteosarcoma/normal fibroblast subcluster.
Supplementary Table S9: *iTALK* output table, showing significant ligand/receptor interactions between selected cell types.

References

1. Meltzer, P.S. and L.J. Helman, *New Horizons in the Treatment of Osteosarcoma.* N Engl J Med, 2021. **385**(22): p. 2066-2076.

2. Chen, X., et al., *Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.* Cell Rep, 2014. **7**(1): p. 104-12.

3. Koirala, P., et al., *Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.* Scientific Reports, 2016. **6**(1): p. 30093.

4. Lussier, D.M., et al., *Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.* Journal for ImmunoTherapy of Cancer, 2015. **3**(1).

5. D'Angelo, S.P., et al., *Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.* Lancet Oncol, 2018. **19**(3): p. 416-426.

6. Tawbi, H.A., et al., *Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.* Lancet Oncol, 2017. **18**(11): p. 1493-1501.

7. Binnewies, M., et al., *Understanding the tumor immune microenvironment (TIME) for effective therapy.* Nature Medicine, 2018. **24**(5): p. 541-550.

8. Corre, I., et al., *The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem.* Cells, 2020. **9**(4): p. 976.

9. Zhu, T., et al., *Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.* Front Immunol, 2022. **13**: p. 907550.

10. Tian, H., et al., *Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.* Bone Research, 2023. **11**(1).

11. Liu, Y., et al., *Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma.* Front Oncol, 2021. **11**: p. 709210.

12. Zhou, Y., et al., *Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.* Nat Commun, 2020. **11**(1): p. 6322.

13. Liu, W., et al., *Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma.* Bone Research, 2023. **11**(1).

14. Zheng, G.X., et al., *Massively parallel digital transcriptional profiling of single cells.* Nat Commun, 2017. **8**: p. 14049.

15. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. **29**(1): p. 15-21.

16. Hao, Y., et al., *Integrated analysis of multimodal single-cell data.* Cell, 2021. **184**(13): p. 3573-3587 e29.

17. Team, R.C., *R: A Language and Environment for Statistical Computing.* 2021.

18. McGinnis, C.S., L.M. Murrow, and Z.J. Gartner, *DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors.* Cell Syst, 2019. **8**(4): p. 329-337 e4.

19. Korsunsky, I., et al., *Fast, sensitive and accurate integration of single-cell data with Harmony.* Nat Methods, 2019. **16**(12): p. 1289-1296.

20. McDavid, A., et al., *Data exploration, quality control and testing in single-cell qPCR-based gene expression experiments.* Bioinformatics, 2013. **29**(4): p. 461-7.

21. Stuart, T., et al., *Comprehensive Integration of Single-Cell Data.* Cell, 2019. **177**(7): p. 1888-1902 e21.

22. Tickle, T., et al., *inferCNV of the Trinity CTAT Project.* 2019.

23. Yuanxin, W., et al., *iTALK: an R Package to Characterize and Illustrate Intercellular Communication.* bioRxiv, 2019: p. 507871.

24. Traag, V.A., L. Waltman, and N.J. van Eck, *From Louvain to Leiden: guaranteeing well-connected communities.* Sci Rep, 2019. **9**(1): p. 5233.

25. Cable, D.M., et al., *Robust decomposition of cell type mixtures in spatial transcriptomics.* Nat Biotechnol, 2022. **40**(4): p. 517-526.

26. Wilcoxon, F., *Individual comparisons of grouped data by ranking methods.* J Econ Entomol, 1946. **39**: p. 269.

27. Schubert, M., et al., *Perturbation-response genes reveal signaling footprints in cancer gene expression.* Nat Commun, 2018. **9**(1): p. 20.

28. Wang, Q., et al., *Role of tumor microenvironment in cancer progression and therapeutic strategy.* Cancer Med, 2023.

29. Neophytou, C.M., et al., *The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities.* Cancers (Basel), 2021. **13**(9).

30. Baghban, R., et al., *Tumor microenvironment complexity and therapeutic implications at a glance.* Cell Commun Signal, 2020. **18**(1): p. 59.

31. Chakarov, S., et al., *Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches.* Science, 2019. **363**(6432): p. eaau0964.

32. Lim, H.Y., et al., *Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.* Immunity, 2018. **49**(2): p. 326-341 e7.

33. Cho, C.-H., et al., *Angiogenic Role of LYVE-1–Positive Macrophages in Adipose Tissue.* Circulation Research, 2007. **100**(4): p. e47-e57.

34. Kieu, T.Q., et al., *Kinetics of LYVE-1-positive M2-like macrophages in developing and repairing dental pulp in vivo and their pro-angiogenic activity in vitro.* Scientific Reports, 2022. **12**(1).

35. Tan, Y., et al., *Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues.* Nat Cell Biol, 2022. **24**(8): p. 1306-1318.

36. Opzoomer, J.W., et al., *Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression.* Science Advances, 2021. **7**(45): p. eabg9518.

37. Cheng, S., et al., *A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells.* Cell, 2021. **184**(3): p. 792-809.e23.

38. Alaluf, E., et al., *Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages.* JCI Insight, 2020. **5**(11).

39. Zeng, X.Y., et al., *M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.* Cancer Biol Ther, 2019. **20**(7): p. 956-966.

40. Condamine, T., et al., *Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.* Sci Immunol, 2016. **1**(2).

41. Jiang, Y., et al., *Single-cell RNA sequencing reveals TCR(+) macrophages in HPV-related head and neck squamous cell carcinoma.* Front Immunol, 2022. **13**: p. 1030222.

42. Fuchs, T., et al., *A combinatorial alphabeta T cell receptor expressed by macrophages in the tumor microenvironment.* Immunobiology, 2017. **222**(1): p. 39-44.

43. Hedrick, C.C. and I. Malanchi, *Neutrophils in cancer: heterogeneous and multifaceted.* Nature Reviews Immunology, 2022. **22**(3): p. 173-187.

44. Alshetaiwi, H., et al., *Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.* Sci Immunol, 2020. **5**(44).

45. Mastio, J., et al., *Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs.* J Exp Med, 2019. **216**(9): p. 2150-2169.

46. Khalil, D.N., et al., *The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.* Nat Rev Clin Oncol, 2016. **13**(5): p. 273-90.

47. Ribas, A. and J.D. Wolchok, *Cancer immunotherapy using checkpoint blockade.* Science, 2018. **359**(6382): p. 1350-1355.

48. Chow, A., et al., *Clinical implications of T cell exhaustion for cancer immunotherapy.* Nat Rev Clin Oncol, 2022. **19**(12): p. 775-790.

49. Zielenska, M., et al., *Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma.* Cancer Genet Cytogenet, 2001. **130**(1): p. 14-21.

50. Ozaki, T., et al., *Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas.* Int J Cancer, 2002. **102**(4): p. 355-65.

51. Forus, A., et al., *Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas.* Genes Chromosomes Cancer, 1995. **14**(1): p. 15-21.

52. Tarkkanen, M., et al., *DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma.* Int J Cancer, 1999. **84**(2): p. 114-21.

53. dos Santos Aguiar, S., et al., *Comparative genomic hybridization analysis of abnormalities in chromosome 21 in childhood osteosarcoma.* Cancer Genet Cytogenet, 2007. **175**(1): p. 35-40.

54. Entz-Werle, N., et al., *Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.* Neoplasia, 2007. **9**(8): p. 678-88.

55. Kresse, S.H., et al., *LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.* Genes Chromosomes Cancer, 2009. **48**(8): p. 679-93.

56. Pompetti, F., et al., *Oncogene alterations in primary, recurrent, and metastatic human bone tumors.* J Cell Biochem, 1996. **63**(1): p. 37-50.

57. Squire, J.A., et al., *High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays.* Genes Chromosomes Cancer, 2003. **38**(3): p. 215-25.

58. Ladanyi, M., et al., *Sporadic amplification of the MYC gene in human osteosarcomas.* Diagn Mol Pathol, 1993. **2**(3): p. 163-7.

59. Maire, G., et al., *Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma.* Neoplasia, 2009. **11**(3): p. 260-8, 3p following 268.

60. Stock, C., et al., *Chromosomal regions involved in the pathogenesis of osteosarcomas.* Genes Chromosomes Cancer, 2000. **28**(3): p. 329-36.

61. Bridge, J.A., et al., *Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature.* Cancer Genet Cytogenet, 1997. **95**(1): p. 74-87.

62. Mertens, F., et al., *Cytogenetic findings in 33 osteosarcomas.* Int J Cancer, 1993. **55**(1): p. 44-50.

63. Taylor, A.M., et al., *Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma.* Int J Mol Sci, 2022. **23**(14).

64. Ohata, N., et al., *Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: involvement of cyclin C in osteosarcoma.* Int J Mol Med, 2006. **18**(6): p. 1153-8.

65. Tarkkanen, M., et al., *Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization.* Cancer Res, 1995. **55**(6): p. 1334-8.

66. Veglia, F., E. Sanseviero, and D.I. Gabrilovich, *Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity.* Nat Rev Immunol, 2021. **21**(8): p. 485-498.

67. Huang, L., X. Xu, and Y. Hao, *The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation.* Rom J Morphol Embryol, 2014. **55**(2 Suppl): p. 501-6.

68. Cannarile, M.A., et al., *Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.* J Immunother Cancer, 2017. **5**(1): p. 53.

69. Tinoco, R., et al., *PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.* Immunity, 2016. **44**(5): p. 1190-203.

70. Kandel, S., et al., *The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.* Cancer Lett, 2021. **510**: p. 67-78.

71. Zhang, C.X., et al., *Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation.* Oncogenesis, 2020. **9**(7): p. 65.

72.	Tao, J., et al., *CD8(+) T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway.* J Cell Mol Med, 2020. **24**(1): p. 1046-1058.

73.	Aarts, C.E.M., et al., *Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair.* Blood Adv, 2019. **3**(22): p. 3562-3574.

74.	Halliday, N., et al., *CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.* Front Immunol, 2020. **11**: p. 600000.

75.	Chou, H.S., et al., *Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells.* Transplantation, 2012. **93**(3): p. 272-82.

76.	Li, Z., et al., *Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-beta in breast cancer progression.* Int J Cancer, 2012. **131**(11): p. 2584-95.

77.	Yang, L., et al., *Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.* Cancer Cell, 2008. **13**(1): p. 23-35.

78.	Wang, X., et al., *EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.* Sci Adv, 2022. **8**(50): p. eabn7983.

79.	Ni, Y., et al., *High TGF-beta signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.* NPJ Precis Oncol, 2021. **5**(1): p. 101.

80.	Pauken, K.E. and E.J. Wherry, *Overcoming T cell exhaustion in infection and cancer.* Trends Immunol, 2015. **36**(4): p. 265-76.

81.	Gumber, D. and L.D. Wang, *Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.* EBioMedicine, 2022. **77**: p. 103941.

82.	Wu, Y., et al., *Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.* Mol Cancer, 2022. **21**(1): p. 184.

Figure 1

Figure 2

Figure 3

Figure 4

A

Major Cell Type	Count	Specific Cell Type	Count	Markers
CD4 T	2126	CD4+ Cytotoxic T	1	*GZMH, CD4, FGFBP2, ITGB1…*
		CD4+ Naive T	50	*TCF7, CD4, CCR7, IL7R…*
		CD4+ Proliferating T	22	*MKI67, TOP2A, PCLAF, CENPF…*
		CD4+ Central Memory T	1748	*IL7R, TMSB10, CD4, ITGB1…*
		CD4+ Effector Memory T	78	*IL7R, CCL5, FYB1, GZMK…*
		Regulatory T cell	227	*CTLA4, FOXP3, TIGIT, CD4…*
CD8 T	3184	CD8+ Naive T	514	*CD8B, S100B, CCR7, RGS10…*
		CD8 Proliferating	19	*MKI67, CD8B, TYMS, TRAC…*
		CD4+ Central Memory T	41	*CD8B, ANXA1, CD8A, KRT1…*
		CD8+ Effector Memory T	2610	*CCL5, GZMH, CD8A, TRAC…*
other T	386	Double-negative T	5	*PTPN3, MIR4422HG, NUCB2…*
		gamma-delta T	135	*TRDC, TRGC1, TRGC2, KLRC1…*
		Mucosal assoc. invar. T	246	*KLRB1, NKG7, GZMK, IL7R…*
NK	738	CD56-dim NK	638	*GNLY, TYROBP, NKG7, FCER1G…*
		Proliferating NK	24	*MKI67, KLRF1, TYMS, TRDC…*
		CD56-bright NK	76	*XCL2, FCER1G, SPINK2, TRDC…*

Figure 5

Figure 6